This is a correction to: Lucia Silla, Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity, Immunotherapy Advances, Volume 3, Issue 1, 2023, https://doi.org/10.1093/immadv/ltac024
In the originally published version of this manuscript, errors were introduced during production steps. Introduction (p2, column b), the subheading should read: “NK cell anti-tumour activity” instead of: “NK zcell anti-tumor activity”. In section NK cell adoptive immunotherapy, p3, column b, second sentence should read: “IL is usually administered during the 14 days following cells infusion, aiming to activate and expand the donor NK cells in vivo.” instead of: “Interleukin (IL) is usually administered during the 14 days following cells infusion, aiming to activate and expand the donor NK cells in vivo.” In section GVL effect without SCT, p6, column a, third sentence should read: “A low- to intermediate-intensity lymphodepletion was started at day -7, followed by IL-2 1 million IU SC beginning on day -1 for a total of six doses.” instead of: “A low- to intermediate-intensity lymphodepletion was started at day 7, followed by IL-2 1 million IU SC beginning on day 1 for a total of six doses.”
The publisher regrets these errors. They have been emended in the article.